FdaApplication
NDA 021677
Identifiers
- fda_app_no: NDA021677
Properties
| Property | Value |
|---|---|
| applicant_name | LILLY |
| application_type | NDA |
Revenue by product
ALIMTA
| Period | Revenue |
|---|---|
| Q4 2023 | $44.9M |
| Q3 2023 | $53.5M |
| Q4 2022 | $236.6M |
| Q3 2022 | $119.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ALIMTA | PEMETREXED | 500MG | INJECTABLE;INJECTION |
1 product